Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
For the fiscal year 2025-26, Emcure Pharmaceuticals reported revenue from operations of INR 92,035 million, an increase of 16.6% year-over-year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were INR 17,886 million, with an EBITDA margin of 19.4%, an improvement of 80 basis points. Profit After Tax (PAT) grew by 33.1% to INR 9,413 million. The company noted that domestic business revenue increased by 10% to INR 40,270 million, while international revenue grew by 22.2% to INR 51,766 million. Research and Development (R&D) investment was INR 3,835 million, representing 4.2% of sales.
Emcure Pharmaceuticals announced the allotment of 11,400 equity shares under its ESOP/ESPS plan on September 11, 2026. This allotment increased the company's paid-up share capital to INR 1,897,106,470 and the number of paid-up shares to 189,710,647. Additionally, the company declared a dividend of ₹3.60 per share, with a record date of September 4, 2026.
As of September 18, 2026, the daily trend for Emcure Pharmaceuticals is indicated as bullish, with the Supertrend indicator at 1844.5. The closing price was ₹2003.8, which is above the 20-day Exponential Moving Average (EMA) of ₹1925.47 and the 50-day EMA of ₹1890.69. However, the monthly trend is indicated as bearish, with the Supertrend at ₹2101.8 and the 14-day Average Directional Index (ADX) at 39.43, suggesting strong momentum but a potential reversal point.
Emcure Pharmaceuticals' 45th Annual General Meeting (AGM) is scheduled to be held via video conferencing on Monday, September 21, 2026, at 11:00 a.m. IST.
As of 18 Sept 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Primary driver: Price swings are higher than typical
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹2,580.45 crore | ₹2,469.70 crore | ₹2,363.48 crore | ₹2,269.82 crore | ₹2,100.54 crore |
| Finance Costs | ₹31.54 crore | PEAK₹46.40 crore | ₹37.98 crore | ₹32.54 crore | ₹26.76 crore |
| Profit Before Tax | PEAK₹393.53 crore | ₹341.18 crore | ₹313.79 crore | ₹341.42 crore | ₹290.76 crore |
| Tax Expense | PEAK₹101.03 crore | ₹97.44 crore | ₹82.42 crore | ₹90.05 crore | ₹75.97 crore |
| Profit Loss For Period | PEAK₹292.49 crore | ₹243.74 crore | ₹231.37 crore | ₹251.37 crore | ₹214.79 crore |
| Paid Up Value Of Equity Share Capital | PEAK₹189.68 crore | ₹189.59 crore | ₹189.57 crore | ₹189.57 crore | ₹189.51 crore |
Revenue from operations reached ₹2,580.45 crore in Q1 FY2026-27, continuing an upward trajectory across the past five consecutive quarters. Sequential growth from Q4 FY2025-26 was 4.48% (₹110.74 crore), while year-over-year growth stood at 22.85% (₹479.91 crore). Other income was minimal at ₹2.07 crore.
Basic and diluted earnings per share both stood at ₹15.50 for Q1 FY2026-27, compared to ₹12.84 in Q4 and ₹10.92 in the year-ago quarter. This represents a 20.72% sequential increase and a 41.94% year-over-year increase. The year-over-year EPS growth exceeded the 36.17% growth in net profit.
Other comprehensive income (OCI) was ₹20.67 crore in Q1, down from ₹33.04 crore in Q4 and significantly lower than ₹79.57 crore in Q1 last year. Combined with net profit, total comprehensive income reached ₹313.16 crore, compared to ₹276.77 crore in Q4 and ₹294.37 crore in Q1 FY2025-26. Total comprehensive income grew 13.1% sequentially and 6.4% year-over-year despite the decline in OCI.
Exchange disclosures and regulatory announcements for Emcure Pharmaceuticals.
On September 11, 2026, Emcure Pharmaceuticals Limited's Nomination and Remuneration Committee approved the allotment of 11,400 equity shares under its ESOP/ESPS plan. This increased the paid-up share capital from INR 1,896,992,470 to INR 1,897,106,470 and the number of paid-up shares from 189,699,247 to 189,710,647.
SERIES:EQ ; PURPOSE:DIVIDEND - RS 3.60 PER SHARE ; FACE VALUE:10 ; RECORD DATE:04-Sep-2026 ; BOOK CLOSURE START DATE:- ; BOOK CLOSURE END DATE:-
Emcure Pharmaceuticals Limited dispatched letters on September 1, 2026, to shareholders who had not registered their email addresses by the August 21, 2026 cut-off date, providing web links and QR codes for the Annual Report 2025-26 and the Notice of the 45th Annual General Meeting. The AGM is scheduled to be held via video conferencing on Monday, September 21, 2026, at 11:00 a.m. IST. The filing also reminded these members to submit TDS exemption documents by September 14, 2026, and to update KYC details to ensure eligibility for dividend payments in electronic mode.
Emcure Pharmaceuticals has scheduled an in-person analyst/institutional investor meeting for September 4, 2026, at 11:00 AM in Pune.
Emcure Pharmaceuticals' FY 2025-26 annual report shows revenue from operations grew 16.6% to INR 92,035 million, crossing the USD 1 billion milestone. EBITDA was INR 17,886 million (margin 19.4%, up 80 bps), and PAT was INR 9,413 million (up 33.1%). The domestic business grew 10% to INR 40,270 million, while international revenue grew 22.2% to INR 51,766 million. R&D investment was INR 3,835 Mn (4.2% of sales). The 45th Annual General Meeting is scheduled for September 21, 2026, via video conferencing.
EMCURE Pharmaceuticals Limited announced its 45th Annual General Meeting scheduled for September 21, 2026, in Pune, to be conducted via video conference. The meeting agenda includes adopting audited financial statements for the fiscal year ended March 31, 2026, and declaring a final dividend of Rs. 3.60 per equity share. Key personnel changes involve the re-appointment of Mrs. Namita Thapar and Dr. Mukund Gurjar as directors, the re-appointment of Mr. Satish Mehta as Managing Director and CEO for a term ending March 31, 2032, and the appointment of Mr. Raghu Kumar as an Independent Director.
Emcure Pharmaceuticals Limited uploaded the transcript of its Q1 FY27 earnings call to its website on August 12, 2026, at 18:36 IST. The call concluded on August 6, 2026, at 16:57 IST, following prior intimation to the exchange on July 15, 2026.
Recent market and company developments associated with Emcure Pharmaceuticals.
Trade Spotlight
Nifty eventually closed 279.50 points lower at 23,118.60, marking its lowest closing level since April 6, 2026
Asian shares remained under pressure as investors assessed escalating Middle East tensions, higher oil prices and elevated bond yields ahead of key c
India Business News: Stock market recommendations: Emcure Pharmaceuticals, and Cholamandalam Investment & Finance Company Ltd - Motilal Oswal Wealth Management Researc.
India Business News: Stock market recommendations: Emcure Pharmaceuticals, and VA Tech Wabag are the top stocks to buy on September 15, 2026, recommends Sudeep Shah, Head .
After a turbulent trading day, Indian stock indices bounced back significantly as oil prices and bond yields eased. The Sensex and Nifty ended with modest declines, having experienced deeper dips earlier. Previous climbs in crude oil prices and geopolitical issues had weighed down on investor confidence. Analysts suggest maintaining caution and closely watching Niftys support and resistance levels, highlighting particular metal stocks and equities to watch for the week ahead.
Adani Power target price, Physicswallah target price, SEAMEC target price, UBL target price, Emcure Pharma target price, Cera Sanitary target price, Kissht target price, IMFA target price, Leela Hotels target price, Apollo Micro target price, Sammaan Capital target price, Adani Power, Physicswallah, SEAMEC, United Breweries, Emcure Pharmaceuticals, Cera Sanitaryware, OnEMI Technology Solutions, Indian Metals & Ferro Alloys, Leela Palaces Hotels & Resorts, Apollo Micro Systems, Sammaan Capital, Adani Power target price, Physicswallah target price, SEAMEC target price, UBL target price, Emcure Pharma target price, Cera Sanitary target price, Kissht target price, IMFA target price, Leela Hotels target price, Apollo Micro target price, Sammaan Capital target price, Motilal Oswal, Choice Institutional Equities, ICICIDirect Research, JM Financial, 360 One Capital, Antique Stock Broking, Systematix Institutional Equities, Ventura
ICICI Direct
Comprehensive Section Breakdown for Emcure Pharmaceuticals
Strategic Vision: Develops, manufactures, and markets pharmaceutical products globally.
• Diverse product portfolio spanning multiple therapeutic areas.
• Global operational footprint across key international markets.
• Focus on developing and manufacturing both pharmaceutical formulations and active pharmaceutical ingredients (APIs).
• Specialization in advanced biologics through a dedicated subsidiary.
Emcure Pharmaceuticals reported revenue of ₹2,580.45 crore for the first quarter of FY2026-27, a 22.85% increase from the same quarter last year. Net profit rose 36.17% to ₹292.49 crore, growing faster than revenue. The bottom-line expansion was supported by a lower effective tax rate and, on a sequential basis, a sharp decline in finance costs. Earnings per share increased to ₹15.50 from ₹10.92 a year ago.
Profit before tax (PBT) increased to ₹393.53 crore, up 15.34% sequentially and 35.35% year-over-year. Net profit (profit for the period) rose to ₹292.49 crore, up 20.00% sequentially and 36.17% year-over-year. The faster growth in net profit relative to revenue indicates improved profitability.
The effective tax rate declined from 28.56% in Q4 FY2025-26 to 25.67% in Q1 FY2026-27, contributing to the net profit increase. On a year-over-year basis, the tax rate also eased slightly from 26.13% to 25.67%.
Reported operating expenses for the quarter included cost of materials consumed at ₹481.14 crore, employee benefit expense at ₹409.50 crore, and depreciation and amortisation at ₹109.51 crore.
Finance costs were ₹31.54 crore, marking a 32.04% sequential decline from ₹46.40 crore in the prior quarter, though they remained 17.87% higher than the year-ago quarter’s ₹26.76 crore. Tax expense increased 3.69% sequentially to ₹101.03 crore and rose 33.00% year-over-year, broadly tracking pre-tax profit growth.
Management highlighted that FY27 is the second year of its five-year plan, focused on delivery, and Q1 results are an encouraging early signal. Revenue grew 22.8% YoY to INR 25,804 Mn, driven by strong international performance (up 34.2%) and resilient domestic growth (up 10.2%). EBITDA margin improved 50 bps to 19.7% due to productivity gains and operating leverage, while PAT grew 36.2% to INR 2,925 Mn. Management expects continued growth over the full year, supported by a strengthened team, portfolio traction, and a robust product pipeline. Recent strategic moves include licensing a novel anti-HPV candidate from ICMR and signing a voluntary licensing agreement with MSD for a generic once-monthly oral HIV PrEP pill, reinforcing the company's commitment to expanding its women's health and global access portfolios.
Emcure Pharmaceuticals delivered a quarter of substantial year-over-year revenue and profit growth, with profit expanding faster than revenue. The improvement was supported by a lower effective tax rate and a sequential decline in finance costs. Earnings per share rose to ₹15.50, reflecting the stronger bottom line. While other comprehensive income declined, total comprehensive income still grew 6.4% year-over-year. The quarter continues a consistent upward revenue trend and demonstrates improved profitability.
Category: Manufacturing
Develops and markets a wide array of formulations including tablets, capsules, injectables, and biotechnology products across therapeutic areas like gynecology, cardiology, oncology, blood-related disorders, and HIV antivirals.
Category: Manufacturing
Produces active pharmaceutical ingredients (APIs) that are essential components for various pharmaceutical formulations.
Category: Biotechnology
Focuses on advancing biologics for life-threatening diseases, with a specialization in cardiology, nephrology, and oncology.
Key Products & Services: Elaxim • Tenectase • Vintor • Xgrast • Pegex • Emgrast M • Hamsyl
Core Thesis: Emcure leverages its diverse product portfolio and global presence to address a wide range of healthcare needs.
• Product Development and Manufacturing: The company is involved in the development and manufacturing of a wide array of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs). • Global Market Presence: Emcure operates globally with a presence in key markets such as India, Europe, Canada, Russia, and Brazil. • Biologics Advancement: Through its subsidiary Gennova Biopharmaceuticals, Emcure focuses on advancing biologics for life-threatening diseases.